Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Galapagos NV ADR is a biotechnology business based in the US. Galapagos NV ADR shares (GLPG) are listed on the NASDAQ and all prices are listed in US Dollars. Galapagos NV ADR employs 1,344 staff and has a trailing 12-month revenue of around $505.1 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $42.85 |
|---|---|
| 52-week range | $41.65 - $72.11 |
| 50-day moving average | $50.02 |
| 200-day moving average | $57.04 |
| Wall St. target price | $65.29 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.01 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $42.85 from 2022-10-03
| 1 week (2022-09-28) | -0.09% |
|---|---|
| 1 month (2022-09-02) | -13.68% |
| 3 months (2022-07-05) | -25.61% |
| 6 months (2022-04-01) | N/A |
| 1 year (2021-10-05) | -15.27% |
|---|---|
| 2 years (2020-10-05) | -70.86% |
| 3 years (2019-10-04) | 151.7 |
| 5 years (2017-10-04) | 103.88 |
| Revenue TTM | $505.1 million |
|---|---|
| Gross profit TTM | $-8,490,000 |
| Return on assets TTM | -1.55% |
| Return on equity TTM | -3.04% |
| Profit margin | -15.96% |
| Book value | $40.27 |
| Market capitalisation | $2.7 billion |
TTM: trailing 12 months
We're not expecting Galapagos NV ADR to pay a dividend over the next 12 months.
Over the last 12 months, Galapagos NV ADR's shares have ranged in value from as little as $41.65 up to $72.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galapagos NV ADR's is 0.231. This would suggest that Galapagos NV ADR's shares are less volatile than average (for this exchange).
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc. ; AbbVie S. Ã r.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.